Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2791)	4/26/2010 11:32:26 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

CPEX is still up 18.89% with volume now close to 37Ks > 3x its ADV <g> bigcharts.marketwatch.com It recommended on Friday that its shareholders take no action at this time in response to the offer by Arcadia Capital Advisors, to acquire all of CPEX outstanding shares for $16.00 in cash.<g> CPEX is making an all time H <g> bigcharts.marketwatch.com The insiders reportedly hold > 30% of the shares. Bernard

To: Jibacoa who wrote (2791)	4/26/2010 12:01:07 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

ARWR is holding on its recent UT. <g> The stock is up a modest 4.58% on volume of 343Ks, still about 1/3 its ADV bigcharts.marketwatch.com It announced today the appointment of Dr. Andrew von Eschenbach to its Scientific Advisory Board. <g> finance.yahoo.com Earlier this month it announced the appointment of Dr. Lee Hartwell to its advisory board.<g> finance.yahoo.com Apparently they think that ARWR's subsidiaries Calandro & Unidym have some potential.<g> But in spite of the ACTAY at $9, I will keep my target unchanged.<g> Bernard